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Abstract
Purpose of review: To discuss the advantages and pitfalls of testing neuroprotective treatment strategies in patients suffering from optic neuritis.
Recent findings: Spectral domain optical coherence tomography (OCT) now permits for automated segmentation of individual retinal layers. The peripapillary retinal nerve
fibre layer (pRNFL) has been used in 13 of the 15 trials reviewed. Twelve trials made use of electrophysiology. Crucially, the overestimation of good visual recovery has
been recognised. Assessment of low contrast visual acuity and colour vision are now mainstream.
Summary: Advantages are the availability of highly accurate and robust trial outcome measures. As a single long–term structural outcome measure the pRNFL is sufficient.
For shorter term assessment the GCIPL and axonal birefringence are promising. Longitudinal blood levels of neurofilament proteins permit to recognise axonal loss at
presentation and monitor changes longitudinally. Inner nuclear layer (INL) volume changes relate to inflammatory disease activity.
Pitfalls are related to the timing of events. Hyperacute recruitment is needed for future trials. The onset of demyelination is not known which complicates timing of
electrophysiological recordings. Optic disc oedema precludes the use of the pRNFL from the affected eye as a baseline variable. The concomitant use of corticosteroids
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Optic neuritis (ON) has been rediscovered as a model disease for human treatment trials in demyelinating diseases [1–3]. With few exceptions the multiple sclerosis (MS)
treatment trial community had turned a blind eye on MS associated ON (MSON) since completion of the influential Optic Neuritis Treatment Trial (ONTT). What has
triggered the renewed interest in ON for human treatment trials?
Treatment of inflammatory disease activity MS is effective. Disease modifying treatments (DMT) reduce the chance for a new relapse by about 30-70% depending on
choice of treatment [4]. Evidence of DMT to halt disease progression has been less convincing.
The attraction of ON as a model disease for neuroprotective treatment trials coincided with the availability of new clinical and paraclinical outcome measures for vision [5].
The expectations are that a treatment trial in MSON can be conducted fast with highly accurate outcome measures. A successful MSON trial can be a promising stepping
stone for neuroprotective treatment strategies in MS at large.
2 Optic neuritis in multiple sclerosis
The presentation of MSON is that of peri-/retro–orbital pain worsening with eye movements which is associated with loss of vision [6]. Recovery is ususally good. Residual
visual symptoms are dyschromatopsia and reduced low contrast visual acuity [5, 6]. Some patients have difficulties with perception of movements in depth (Pulfrich
phenomenon) and transient worsening of vision related to changes in body temperature (Uhthoff phenomenon).
3 Relevant trial design implications from the diagnostic work–up of acute optic neuritis
Ahmet Toosy has reviewed the general assessment of patients with MSON in this issue of the Journal. Practically, the diagnosis of acute ON within days after onset is much
more challenging than after about three months [6]. Many of the classical symptoms and signs will not yet have developed. Recognising the about 5% of patients with ON
who have a poor visual outcome at presentation is challenging [7]. Contamination of neuroprotective optic neuritis treatment trials with these patients is a real possibility.
Exclusion of other aetiologies of autoimmune visual loss in the acute phase requires testing for auto–antibodies [8, 9].
4 Outcome measures for neuroprotective treatment trials in optic neuritis
The key pathological features used as an outcome measure in MSON are demyelination and axonal loss. Currently, demyelination is recorded using electrophysiology.
Axonal loss in the retina is assessed with OCT. Axonal loss in the optic nerve, optic tracts and optic radiations is assessed by MRI.
Visual function is assessed with high and low contrast visual acuities, contrast sensitivity, colour vision tests and visual field tests [5, 6].
Visual quality of live is documented with validated patient questionnaires. The 25-Item National Eye Institute Visual Function Questionnaire (NEI-VFQ-25) has been
extended by a neuro–ophthalmology supplement [10].
Remyelination Inflammation at onset of MSON is sufficient to cause conduction block in the optic nerve. Inflammation precedes demyelination. Because the nadir of
demyelination is not known, assessment of demyelination/remyelination is difficult. It is not known at which time point after onset of acute MSON visual function and
electrophysiology are best to be recorded. This will remain a tricky problem for optic neuritis treatment trial design.
A clinical outcome measure for remyelination may be presence of Uhthoff phenomenon during the recovery phase from MSON [11].
4.1 Electrophysiology
The electrophysiological tests are of particular value in studies evaluating therapy [3, 12]. The International Society for Clinical Electrophysiology of Vision (ISCEV)
(www.iscev.org/standards/proceduresguide.html) specifies the standards, gives recommendations and provides guidelines on testing [13]. For optic neuritis treatment trials
relevant tests to consider are the Pattern Appearance Visually Evoked Cortical Potential (VEP) and the Pattern Electroretinogram (PERG) [6, 14]. Demyelination of the
optic pathways results in delay of the VEP P100 amplitude. The accepted wisdom is that recovery of conduction velocity indicates remyelination. The challenge is to
capture the right moment.
The PERG not only permit for early detection of retinal pathology, but also shows a reduction of the N95 component in affected eyes [15]. The multifocal ERG (mfERG)
permits for more detailed spacial analysis and shows a reduced optic nerve head component (ONHC) response following demyelination [16].
4.2 OCT
Retinal has become one of the best validated and sensitive outcome measures for neurodegeneration following MSON [5, 6, 17]. The field recognised early the need for
standardised OCT acquisition procedures, quality control (QC) and reporting guidelines [18–20].
RNFL The peripapillary retinal nerve fibre layer (pRNFL)is a higly robust long term outcome measure for MSON treatement trials. Following optic neuritis there is
substantial axonal damage [7]. At presentation this can be masked by presence of optic disc oedema [21]. Longitudinal studies demonstrate that atrophy of the pRNFL
becomes manifest within about three months and plateaus after about one year [2, 22]. Atrophy of the pRNFL after MSON in a meta–analysis of cross–sectional studies
averaged at 20 μm (95%CI 18-23 μm) using time domain OCT [23]. The annual atrophy rate of the pRNFL was highest in patients with MSON and a short disease duration
[24, 25].
GCIPL The ganglion cell / inner plexiform layer (GCIPL) is a valuable early response outcome measure. The GCIPL has the important advantage that optic disc oedema
does not reach the macular, hence atrophy can be detected about two month earlier than in the RNFL [22].
INL The inner nuclear layer (INL) is a promissing outcome measure for inflammation. In MS there is evidence that INL volume changes are related to inflammatory
disease activity and respond to DMT [26]. These rapid transient volume changes were hypothesised to be caused by fluid shift in an impairment retinal glymphatic system
[27]. Longitudinal INL volume assessments may inform on inflammatory disease activity in MSON treatment trials.
5 Pupillography
As discussed in detail by Finn Bremner in this issue, infrared video pupillography permits with high accuracy to record of a dynamic pupil response under controlled
conditions. This provides an objective assessment of the relative afferent pupillary defect (RAPD) observed in MSON. The development of hand held pupillometer devices
has now reached a level of reliability suitable for multi–centre trials [28].
5.1 MRI
Optic neuritis treatment trials may include MRI for diagnostic reasons, to exclude other relevant co–morbidity and for safety reasons. The recommended sequences for the
optic nerve are to be taken in coronal orientation and take about 10 minutes. They include T2-weighted images with fat suppression (e.g., STIR, SPIR) and T1-weighed
images before and after contrast administration [6, 29, 30]. For assessment of tissue integrity a range of additional techniques are available, such as high resolution 3D T2–
weighted (CISS) images for the visualisation and volume measurements of the optic nerve and diffusion tensor imaging (DTI) [17, 31]. There is experimental and human
post–mortem evidence to suggest a role of DTI and high field MRI for assessment of remyelination [32]. Longitudinal studies will need to take into account that there is a
relevant effect of using different scanners over time [33].
6 Neuroprotective treatment trials
Figure 1 gives an overview on compounds and strategies reviewed. The primary and secondary outcome measures have been summarised in Table 1.
Adrenocorticotropic hormone One phase 0 (NCT01987167) and one phase 4 (NCT01838174) investigate the neuroprotective role of adrenocorticotropic hormone
(ACTH, synonymous corticotropin in MSON. It is hypothesised that melanocortin-mediated anti-inflammatory effects of ACTH will be neuroprotective in MSON. Patients
in one trial (NCT01838174) also receive intravenous methylprednisolone therapy (IVMP).
Amiloride Two phase 2 trials (NCT01879527, NCT01802489) test for the neuroprotective effect of amiloride in MSON [34]. Amiloride is approved as a diuretic.
Amiloride blocks the acid sensing ion channel 1 (ASIC1) which controls Na2+ and Ca2+ fluxes. Blockage of cytotoxic cellular overload with Ca2+ could be
neuroprotective in MSON. The primary outcome measure was the scanning laser polarimetry (GDx) derived pRNFL in addition to the OCT pRNFL. The GDx
methodology relies on birefringence of the RNFL [23]. Birefringence is related to the structure of dominant axonal filaments such as the neurofilament protein. Because
neurofilament protein composition changes with axonal injury and precedes axonotmesis it had been hypothesised that changes of RNFL birefringence may represent the
earliest sign of axonal degeneration in MSON [23]. The Amiloride trial in MSON has however been reported as negative with regard to the primary outcome measures
(ECTRIMS, 15.09.2016, McKee et al., Talk 102). What can be learned from the trial however, is that the baseline GDX pRNFL was less affected by optic disc oedema
compared to the OCT derived pRNFL.
Unexpectedly one of the secondary outcome measures, the VEP latencies, were found to be delayed by 12.81 ms in the treatment arm (27.27 ms) if compared to placebo
(14.45, p=0.0043) at six months. This may imply that amiloride impedes remyelination.
It should also be remembered that patients were recruited within up to 28 days (mean 14 days) of onset which may have been too late.
Atacicept One phase 2 trial (2007-003925-26) gave the recombinant fusion protein atacicept. Atacicept inhibits B–cells. Mature B- and plasma cells are more likely to
blocked then memory B–cells and progenitor cells. Corticosteroids may be given optionally to treat the initial ON event. The trial was prematurely stopped. Disease
activity was higher in the treatment arm [35]. The data available showed a minimal effect of atacicept on pRNFL atrophy.
Cholecalciferol There is evidence patients with MSON and low vitamin D levels have more severe atrophy of the pRNFL and GCL [36]. There is one ongoing phase 3
(2010-018498-39) testing the potential neuroprotective effect of cholecalciferol in acute MSON.
Clemastine An exciting translational research line as lead to the discovery of clemastine fumarate as a compound stimulation remyelination [37]. Clemastine (meclastin)
has antihistaminic and anticholinergic properties and is used for treatment of allergic rhinitis. A phase 2 study (NCT02040298) demonstrated significant improvement of
P100 latency delay by about 1.9 ms/eye during the treatment period (presented at the American Academy of Neurology’s 68th Annual Meeting in Vancouver, Canada,
April 15 to 21, 2016). A phase 2 trial for acute MSON is ongoing (NCT02521311). Patients will also receive IVMP or oral prenisolone.
Corticosteroids One major result of the ONTT was that most neurologists switched from oral to intravenous corticosteroid treatment for MSON [38]. An important recent
trial demonstrated the non inferiority of oral high–dose (1000 mg) methylprednisolone for 3 days compared to IVMP (1000 mg) [39]. No placebo controlled trial of oral
corticosteroids had been published since 1999 according to the last systematic Chochrane review [40]. Since, a randomised single blinded clinical trial had completed
suggesting no inferiority of oral compared to intravenous corticosteroids (ECTRIMS 15.09.2016, S.A. Morron, poster 660).
There is anecdotal evidence that hyperacute treatment with corticosteroids in MSON may be neuroprotective [41, 42]. One phase 4 trial (2012-002628-34) evaluates early
treatment with high–dose IVMP.
Erythropoietin The glycoprotein hormone erythropoietin (EPO) boosts red blood cell production. Consistent with experimental evidence for neuroprotective properties of
EPO a phase 2 MSON treatment trial (NCT00355095) was successfully concluded [43]. Treatment with EPO lead to significantly less pRNFL atrophy (OCT), optic nerve
atrophy (MRI) and better VEP latencies. Patients in this trial also received IVMP. The median time from onset to treatment was 4 days for EPO/IVMP and two days later
for IVMP. Whether or not early treatment with IVMP may have caused a bias is not known. A follow–up phase 3 trial (NCT01962571) is ongoing [44].
Fingolimod A phase 2/3 trial with Fingolimod (2011-004787-30) in MSON was prematurely terminated due to poor recruitement.
Minocycline Two phase 2 trials (NCT01073813, 2011-001589-16) examine the neuroprotective effect of the tetracycline antibiotic minocycline in MSON. Minocycline has
multi-level anti–apoptotic properties and reduces glutamate toxicity.
Opicinumab Differentiation of oligodendrocytes is inhibited by membrane glycoproteins to which LINGO-1 belongs [3]. A phase 2 trial with Opicinumab (NCT01721161)
has completed. Treatment with Opicinumab was associated with an increased VEP latency recovery (22.24 ms) compared to placebo (14.69, p=0.0504). There was no effect
on the pRNFL (-11.75 μm vs 15.66 μm), GCIPL (-9.9 vs -11.05) or LCVA. The trial has been extended (NCT02657915).
Phenytoin There is good translational and preclinical data on the neuroprotective effect of ion channel blocking agents [34]. A phase 2 trial with the anti-epileptic drug
phenytoin was positive for the primary outcome measure. There was significantly less atrophy (-7.15 μm) of the pRNFL in the treatment group if compared to the placebo
group [45]. Likewise thinning of the total macular volume (-0.20 mm3) was less marked in the treatment group. Atrophy of the GCIPL, thought to be a good biomarker
because less affected by the baseline disc oedema compared to the pRNFL, did however not differ significantly between the treatment group and placebo (ECTRIMS,
15.09.2016, R. Kapoor, Talk 99). Of the secondary outcome measures, blood derived neurofilament heavy chain levels were significantly lower in patients treated with
phenytoin compared to placebo (ECTRIMS 16.09.2016, S. Gnanapavan et al. Poster 1619). None of the clinical outcome measures reached significance.
The average time from onset to randomisation was 8 days in both groups. Patients were given the choice to have IVMP. More patients in the treatment group received
IVMP (85%) compared to the placebo group (75%).
Simvastatin There is in–vitro, translational, preclinical and clinical evidence for favourable immunological effects and neuroprotection of statins in demyelination,
particularly in secondary progressive MS [46]. A phase 3 trial suggested improved recovery of colour vision and VEP latency amplitude in patients treated with statins [47].
The average time from symptom onset to treatment was 12 days for statins and 15 days for placebo.
7 Conclusion
Compared to the past two decades, the last two years have been exiting and thought stimulating data regarding the treatment of patients with MSON. Six compounds are in
phase 2 and 5 in phase 3/4. With one exception, opicinumab, all compounds have already been approved for different conditions.
Retinal OCT has clearly become the favourable structural outcome measure, being included in 13/15 (86%) of the trials. The most frequently employed functional
paraclinical outcome measure is the VEP latency in 12/15 (80%) of trials. Well thought through timing of the VEP assessement is crucial to capture the moment of optic
nerve demyeliation. Presently, short interval longitudinal VEP recordings may be required.
Because of the small effect size of the pRNFL and VEP latencies in the published trials it cannot be overemphasised how important it is to have a rigorous quality control
pipeline in place in order to avoid data contamination [Sch2014_c, 13, 19, 20].
Ten studies detailed MRI sequences with assessment of optic nerve diameter being useful for assessment of atrophy. Likewise coronal T2 weighted images with fat
suppression and coronal T1 Gd enhancing images are extremely useful for confirmation of presence and location of optic nerve inflammation. There is a plethora of
exciting MRI research sequences which investigate diffuse tissue damage.
Of the novel outcome measures two trials included a biomarker for axonal degeneration, the neurofilament protein; one trial employed pupillography.
The time from symptom onset to treatment initiation in MSON is still rather long compared to what has been achieved in stroke medicine. There is anecdotal evidence for a
beneficial effect of hyperacute treatment. We have achieved same day treatment in the vast majority of patients presenting with transient monocular blindness at Moorfields
Eye Hospital by tapping into established stroke pathways. Similar efforts need to be done for MSON.
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